Long-term carvedilol therapy effects on left ventricular remodeling and glycemia in patients with chronic heart failure and Type 2 diabetes mellitus

Long-term carvedilol therapy effects on left ventricular remodeling and glycemia in patients with chronic heart failure and Type 2 diabetes mellitus

Aim. To study the effects of long6term carvedilol treatment on left ventricular (LV) remodeling and glycemia control parameters in patients with chronic heart failure (CHF) due to post6infarction cardiosclerosis, and Type 2 diabetes mellitus (DM-2).Material and methods. This 12-month study included...

Full description

Saved in:

Bibliographic Details
Main Authors:	R. R. Samedov, A. B. Bakhshaliev
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2008-02-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	type 2 diabetes mellitus chronic heart failure beta-adrenoblockers carvedilol
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1062
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

BETA-BLOCKERS AND RENOPROTECTION: THE POTENTIAL OF CARVEDILOL
by: I. T. Murkamilov, et al.
Published: (2017-07-01)

Carvedilol and bisoprolol effectiveness in patients with myocardial infarction and heart failure
by: A. I. Chesnikova, et al.
Published: (2008-06-01)

ESTIMATION OF CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC CARVEDILOLS IN PATIENTS WITH HYPERTENSION OF 1-2 GRADES
by: E. I. Bambysheva, et al.
Published: (2016-01-01)

Carvedilol therapy effects on structural and electric remodeling in chronic heart failure
by: E. V. Minakov, et al.
Published: (2008-02-01)

COMPARISON OF THE INFLUENCE OF LONG-TERM TREATMENT BASED ON CARVEDILOL OR BISOPROLOL ON METABOLIC PARAMETERS IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY RESULTS OF THE RANDOMIZED OPEN-LABEL PARALLEL-GROUPS STEPPED TRIAL CABRIOLET (PART I)
by: S. Y. Martsevich, et al.
Published: (2015-12-01)

Carvedilol and its combination with digoxin for heart rate control in patients with persistent atrial fibrillation and chronic heart failure
by: S. N. Tereshchenko, et al.
Published: (1970-01-01)

COMPARISON OF THE INFLUENCE OF LONG-TERM TREATMENT BASED ON CARVEDILOL OR BISOPROLOL ON METABOLIC PARAMETERS AND ERECTILE FUNCTION IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY RESULTS OF THE RANDOMIZED OPEN-LABEL PARALLEL-GROUPS STEPPED TRIAL CABRIOLET (PART 2)
by: S. Y. Martsevich, et al.
Published: (2015-12-01)

BETA-ADRENOBLOCKERS AND PLATELET AGGREGATION. CARVEDILOL
by: A. N. Zakirova, et al.
Published: (2016-01-01)

COMPARISON OF CARVEDILOL AND BISOPROLOL EFFICACY IN PATIENTS WITH CHRONIC HEART FAILURE AND DIABETES TYPES 2 AFTER MYOCARDIAL INFARCTION
by: M. E. Statsenko, et al.
Published: (2016-01-01)

Cardioselective beta-adrenoblocker bisoprolol in treating hypertensive patients with heart failure
by: A. N. Britov
Published: (2005-06-01)

Beta-adrenoblocker in heart failure: bisoprolol role
by: Yu. V. Lukina, et al.
Published: (1970-01-01)

Differential beta-adrenoblocker therapy in chronic heart failure
by: S. N. Tereshchenko, et al.
Published: (1970-01-01)

THE EFFECTIVENESS OF CARVEDILOL AND EPROSARTAN IN PATIENTS WITH METABOLIC SYNDROME AND CHRONIC HEART FAILURE
by: R. L. Dashnamirov
Published: (2014-04-01)

Carvedilol effectiveness in complex treatment of patients with arterial hypertension, coronary heart disease, and Type 2 diabetes mellitus
by: R. M. Shakirova, et al.
Published: (2007-10-01)

Differential approach in selecting beta-adrenoblocker therapy for patients with chronic heart failure and anaemia
by: T. M. Uskach, et al.
Published: (2012-04-01)

THE ROLE OF CARVEDILOL IN THE PREVENTION OF CARDIOMYOCYTE APOPTOSIS CAUSED BY ACUTE MYOCARDIAL INFARCTION
by: A. N. Zakirova, et al.
Published: (2017-12-01)

METOPROLOL AND CARVEDILOL IN THERAPY OF ACUTE MYOCARDIAL INFARCTION: WHEN AND WHICH DRUG TO PREFER
by: B. N. Garifullin, et al.
Published: (2016-01-01)

Status and function of betaDadrenoreceptors and their modification during betaDblocker treatment in patients with arterial hypertension and chronic heart failure
by: O. A. Maneshina, et al.
Published: (2005-10-01)

THE PLACE OF NEBIVOLOL IN RATIONAL THERAPY OF CONGESTIVE HEART FAILURE
by: A. B. Khadzegova
Published: (2014-09-01)

COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL
by: S. Y. Martsevich, et al.
Published: (2016-01-01)

COMPARISON OF THERAPIES BASED ON CARVEDILOL AND METOPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY. THE FIRST RESULTS OF CAMELLIA TRIAL
by: S. Y. Martsevich, et al.
Published: (2016-01-01)

The comparative analysis of the influence of bisoprolol and carvedilol on the course of heart failure of ischemic origin in patients with concomitant atrial fibrillation and diabetes mellitus
by: N.M. Kulaiets, et al.
Published: (2024-11-01)

Differential beta-adrenoblocker therapy in chronic heart failure: the role of age, gender, and co-morbidity
by: S. N. Tereshchenko, et al.
Published: (2009-10-01)

EVALUATION OF CARVEDILOL EFFECTS ON THE BASIC DATA OF LEFT VENTRICLE SYSTOLIC AND DIASTOLIC FUNCTION AFTER ACUTE MYOCARDIAL INFARCTION
by: L. N. Mingazetdinova, et al.
Published: (2001-08-01)

ARTERIAL HYPERTENSION IN PATIENTS WITH DIABETES MELLITUS: AN INDIVIDUALIZED CHOICE OF ANTIHYPERTENSIVE MEDICATIONS
by: T. E. Morozova, et al.
Published: (2011-04-01)

EFFECTS OF CARVEDILOL AND METOPROLOL ON VEGETATIVE REGULATION OF HEART AND MICROCIRCULATION IN PATIENTS WITH HYPERTENSION AND HIGH BODY MASS
by: A. R. Kiselev, et al.
Published: (2016-01-01)

EFFECTS OF Β-ADRENOBLOCKERS ON MYOCARDIAL REMODELING, IMMUNO-INFLAMMATORY REACTIONS AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ISCHEMIC HEART DISEASE AND CHRONIC HEART FAILURE
by: A. N. Zakirova, et al.
Published: (2015-12-01)

COMPARATIVE EFFICACY OF CHRONIC HEART FAILURE TREATMENT WITH PERINDOPRIL OR CARVEDILOL IN PATIENTS WITH ALCOHOLIC OR IDIOPATHIC DILATED CARDIOMYOPATHY
by: I. V. Zhirov, et al.
Published: (2015-09-01)

HEART FAILURE, DIABETES, BETA-BLOCKERS AND RISK OF HYPOGLYCEMIA
by: A. A. Aleksandrov, et al.
Published: (2016-01-01)

BETA-ADRENOBLOCKER THERAPY IN ARTERIAL HYPERTENSION, METABOLIC DISTURBANCES, AND TYPE 2 DIABETES MELLITUS
by: D. V. Nebieridze, et al.
Published: (2009-08-01)

RATIONAL CHOICE OF Β-ADRENOBLOCKERS IN CHRONIC HEART FAILURE THERAPY
by: M. L. Maximov
Published: (2015-12-01)

Experimental Design Approach for the Formulation of Controlled Release Buccal Bilayer Tablets of Carvedilol
by: Vinodkumar D. Ramani, et al.
Published: (2018-07-01)

EFFECTS OF BETA-BLOCKER METOPROLOL ON QUALITY OF LIFE IN ELDERLY PATIENTS WITH CHRONIC HEART FAILURE
by: I. V. Vologdina
Published: (2015-12-01)

Current position of beta-adrenoblockers in coronary heart disease management: information for clinicians
by: I. A. Libov, et al.
Published: (2009-04-01)

Carvedilol: New pharmacological approaches
by: Mohamed Alaa Hafez, et al.
Published: (2024-12-01)

Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity?
by: Szponar Jaroslaw, et al.
Published: (2024-12-01)

DIASTOLIC DYSFUNCTION AND REMODELING OF THE LEFT VENTRICULAR DEPENDING ON THE CONTROL OF GLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: A. E. Kratnov, et al.
Published: (2014-06-01)

Clinical and hemodynamic effects of carvedilol in patients with hypertrophic cardiomyopathy
by: T. A. Abdullaev, et al.
Published: (1970-01-01)

Stable coronary heart disease treatment: focus on beta-adrenoblockers
by: V. I. Makolkin
Published: (2008-12-01)

Efficiency of betaadrenoblockers in pregnant women with idiopathic ventricular tachycardia
by: E. A. Pripachkina, et al.
Published: (2018-02-01)